Figure 6
Pharmacological doses of FVIIa protects against intestinal bleeding, bodyweight loss, and disease activity in DSS-induced colitis in wild-type but not EPCR−/− mice. Wild-type or EPCR−/− mice were administered with a control vehicle (saline) or recombinant hFVIIa (250 µg/kg) every alternate day during the 10-day course of colitis, starting at day 1 of DSS-treatment. The body weight loss (A) and disease activity index (B) were measured. (C) Representative images of the colon collected from control and FVIIa treated mice. (D) The colon length measurements. Data are the mean ± SEM of 2 independent experiments of 8 mice/group. In panels A and B, data of DSS-fed wild-type mice were compared with FVIIa-treated DSS-fed wild-type mice, DSS-fed EPCR−/− mice, or FVIIa-treated DSS-fed EPCR−/− mice to determine statistical significance. *P < 0.05; **P < 0.01; ***P < 0.001.
